Rosalind Franklin University of Medicine and Science, North Chicago, IL
Zeeshan Muzammil, Ramji Ramaswamy Rajendran, Alex Gordon
Background: Applications of virtual reality (VR) have impacted every sphere of civilization, from speculative architecture to the practice of medicine. Building on the body of research already showing the benefits of immersive VR experiences, the goal of our study was to determine whether the stress and anxiety experience of different types of cancer could be mitigated by using virtual reality, specifically through relaxing VR experiences. Methods: A comparative observational study was conducted at community outpatient offices for patients who wanted to improve patient experience throughout their cancer treatment. Patients who had symptoms of nausea, dizziness, and vision issues were excluded from the study. The VR intervention consisted of patients watching a relaxation VR 360 video on the YouTube app every day for one week on the Google Cardboard VR headset. Pre- and post VR intervention scores were recorded using a DASS21 questionnaire. The mean differences in scores as well as t-tests were compared between individuals to see if VR improved patient’s experience through one’s cancer treatment. Results: There were 115 subjects (n = 115). There was an average reduction score of 6.50 points with stress seeing the biggest drop in score of 2.71 points. Breast cancer was the most common cancer diagnosis. Metastatic cancer was the cancer with the biggest change in VR intervention with an average decrease of 12.83 points. Conclusions: Virtual reality (VR) has been proven to significantly reduce the psychological discomfort, including stress, anxiety, and depression experienced during treatment, in the context of caring for cancer patients. The empirical results strongly imply that VR is an effective therapeutic intervention modality in the inpatient setting, with compelling implications for the use of VR technology in the future to lessen the physical and psychological suffering of cancer patients.
Outcome measurement across all DASS categories. | ||||||
---|---|---|---|---|---|---|
Measure | Comparison | Mean Difference | 95% CI | t-statistic | df | p-value |
DASS Total | Post vs Pre | -6.50 | [-8.17, -4.82] | -7.67 | 114 | < 0.001 |
DASS Depression | Post vs Pre | -1.91 | [-2.57, -1.26] | -5.78 | 114 | < 0.001 |
DASS Anxiety | Post vs Pre | -1.89 | [-2.48, -1.30] | -6.33 | 114 | < 0.001 |
DASS Stress | Post vs Pre | -2.71 | [-3.42, -2.00] | -7.56 | 114 | < 0.001 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Sean R. Zion
2023 ASCO Annual Meeting
First Author: Santhanam Sundar
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Judy Li
2019 Supportive Care in Oncology Symposium
First Author: Areej El-Jawahri